Tandem Diabetes stock falls after Citi downgrades to Sell on competition concerns

Published 09/07/2025, 13:10
© Reuters.

Investing.com -- Tandem Diabetes Care (NASDAQ:TNDM) stock fell 5% Wednesday morning after Citi downgraded the medical device maker to Sell from Neutral, citing intensifying competitive pressures.

Analyst Joanne Wuensch slashed the price target to $14 from $24, implying a potential 16% downside from Tuesday’s closing price of $16.62. The downgrade triggered selling in premarket trading as investors digested concerns about the company’s growth prospects.

"While the 2Q25 delivery will be imperative, commentary on competition and the impact of potential competitive bidding will be top of mind," Wuensch wrote in a note to clients. She added that competition remains stiff and sees potential pressures from competitive bidding.

The analyst expressed skepticism about Tandem’s ability to overcome these challenges in the near term. "With these competing pressures, we believe it will be difficult for TNDM to trade upwards, and likely will remain pressured," Wuensch noted.

Tandem Diabetes Care manufactures insulin delivery systems for people with diabetes, operating in a market with several established competitors. The company faces headwinds not only from existing rivals but also potential pricing pressures from competitive bidding processes in the medical device sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.